VaxyGen and Georgia State University enter collaboration and licensing agreement
VaxyGen Manufacturing Services, a Georgia Research Alliance VentureLab company, has entered an exclusive license and collaboration agreement with the Georgia State University Research Foundation to provide the company with exclusive rights to a novel patent for producing and purifying proteins in development as biopharmaceutical and vaccine products. The collaboration agreement is to commercialize the work of the GSU Biological Process Development and Research Laboratory. In addition to introducing VaxyGen’s president and CEO David Dodd to researchers at GSU, GRA has invested in equipping the Biological Process laboratory. Read more here>
Entry filed under: News.